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Posttranslational modifications (PTMs) control protein function, but established peptide-based proteomic
methods often fail to provide a comprehensive view of PTMs. In this issue of Chemistry & Biology, Gersch
et al. describe an efficient combination of chromatographic separation and top-down mass spectrometry
that together with an intuitive visualization tool allowed them to screen the proteasome for PTMs and cova-
lently binding inhibitors.Most proteins contain posttranslational
modifications (PTMs) that are essential
for their biological function. Given this
importance, analytical methods devel-
oped to detect such modifications have
become increasingly important. Among
these methods, mass spectrometry
(MS)-based proteomics has emerged as
the most powerful approach due to its
sensitivity, lack of bias toward certain
proteins, and high-throughput capabil-
ities (Mann and Jensen, 2003; Witze
et al., 2007). However, well-established,
routinely usedproteomicsmethodsbased
on tryptic digest of proteins followed by
LC-MS/MS-analysis of the resulting pep-
tides (known as bottom up proteomics)
do not allow for comprehensive account-
ing of all PTMs due to several reasons. In
reality, not all resulting peptide fragments
will be found again, leading to incomplete
sequence coverage. Another drawback is
that peptides may not be specific for indi-
vidual protein species or evenproteins. In-
formation about complex combinations of
PTMs (e.g., on histones) and their relation
to each other is also lost because they
occur on disparate peptides. Moreover,
some PTMs, especially phosphorylation,
are cleaved more easily than the peptide
backbone by commonly used fragmenta-
tion techniques (collision-induced disso-
ciation), hindering identification of the
site of modification. In order to overcome
these limitations, intact protein mass
spectrometry and top-down proteomics
have been developed in which the mass
of the intact protein and its fragments
is determined with high-resolution mass
spectrometry. For this purpose, FT-ICR-
MS (Fourier-transform ion cyclotron reso-
nance) instruments are commonly used,which, depending on their magnetic field,
allow mass differences of < 1 ppm (part
per million; e.g., < 0.02 Da for a 20 kDa
protein) to be measured and, due to com-
plete sequence coverage, individual pro-
tein species to be fully characterized.
The proteasome has been a natural
testing ground for such MS-based
methods in the search of PTMs (Laksh-
mananetal., 2014, Looetal., 2005,Sharon
et al., 2007).Ononehand, it is of special in-
terest because of its high biological and
clinical relevance as the most important
player in protein breakdown in the cell;
on the other hand, it represents an analyt-
ical challenge of considerable complexity
featuring various catalytic and noncata-
lytic subunits, which are assembled differ-
ently dependingon thediseasestate of the
cell and numerous PTMs, such as Ser/Thr
phosphorylation, N-terminal acetylation,
and N-terminal truncation. This results in
sample heterogeneity, which has imposed
limitations on the analysis of samples and
resulting data.
Sieber and coworkers (Gersch et al.,
2015) present a straightforward analytical
platform for PTM analysis of protein com-
plexes, in which reversed-phase chroma-
tography that allowed subunit separation,
and concomitant FT-ICR-MS analysis
were integrated to an intact protein LC-
MS workflow. They devised a new data
analysis tool called RoWinPro (rolling win-
dow spectral deconvolution of intact pro-
tein mass spectrometry datasets), which
provides an automated analysis of the
sets of scans over the complete run and
very nicely visualizes shifts in retention
time andmass resulting frommodification
of protein subunits in a 2D map. With
this combination of techniques, GerschChemistry & Biology 22, March 19, 2015et al., (2015) achieved several interesting
findings.
The separation of protein subunits and
subsequent HR-MS allowed for the inves-
tigation of the phosphorylation pattern
of the proteasome subunits. The authors
could confirm that the a7 phosphorylation
is the only phosphorylation site in the
yeast and human 20S proteasomes.
In a second line of research, Gersch
et al., (2015) used their technique to study
the interaction of the proteasome inhibitor
carfilzomib, which is a clinically used anti-
cancer drug, with the catalytic subunits of
the proteasome and identify its covalent
interaction points (Figure 1). While top-
down MS has been used for studying
PTMs before, it has been done less so
for covalent modification by small mole-
cule inhibitors. Considering the increasing
interest in activity-based protein profiling
(ABPP) and the renaissance in covalently
binding drugs, this analytical tool will be
of tremendous value for such research.
In summary, Gersch et al. (2015) have
presented a very efficient analytical
platform that allowed them to obtain a
comprehensive view of covalent modifi-
cations of the subunits of the proteasome.
Their tool should be of great help for
research in posttranslational modification
and covalent drug actions, especially in
the context of protein complexes.
We expect that the recent develop-
ments will greatly increase the implemen-
tation of intact protein mass spectrom-
etry and top-down proteomics in the
scientific community. On the one hand,
very sensitive, very high-resolution mass
spectrometers have become available
that allow the detection of the broad iso-
topic patterns of high-molecular-weightª2015 Elsevier Ltd All rights reserved 315
Figure 1. Visualization of Covalent Modification with Sample Maps
Green spots, protein subunits unaffected by covalent modification; orange
spot, protein subunit in the absence of covalent inhibitor; blue spot, protein
subunit after incubation with covalent inhibitor.
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proteins, next to small mass
shifts introduced by PTMs
(e.g., a disulfide bridge
causes a mass difference
of 2 Da). On the other
hand, intact protein separa-
tion methods have been
improved, which increases
the sensitivity of the tech-
nique and allows top down
profiling of complex pro-
teomes (Catherman et al.,
2014). Furthermore, suitable
software for processing of
top down proteomic data,
such as the first software,
ProSight PTM, developed
and further improved by Kel-
leher and coworkers for topdown LC-MS/MS data (Taylor et al.,
2003, LeDuc et al., 2004, Zamdborg
et al., 2007, Tran et al., 2011, Durbin
et al., 2014), or the RoWinPro tool intro-
duced by Gersch et al. (2015) for intact
protein LC-MS data is now available.
Together, both recent software and
method development are pushing the
limits of what can be analyzed and will
likely lead to new functional insights.316 Chemistry & Biology 22, March 19, 2015REFERENCES
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